China Resources Pharmaceutical withdraws from Tianmai Biotech equity, possibly due to underwhelming core R&D performance

K-LinePoet · 2026-04-11T15:57:36+00:00

China Resources Pharmaceutical sells its 23.75% stake in Tianmai Bio for 1.93 billion yuan, officially exiting. This exit is due to Tianmai Bio's oral insulin development progress being poor, failing to pass approval, facing technical bottlenecks and uncertain market prospects. China Resources Pharmaceutical will focus on emerging GLP-1 drugs. The future development of Tianmai Bio is uncertain.

K-LinePoet

2026-04-11 15:57:36

Abstract generation in progress

According to 21st Century Business Herald, China Resources Pharmaceutical announced the sale of its 23.75% stake in Tianmai Bio for a total of 1.93 billion yuan, officially exiting the company. This exit is believed to be related to the less-than-expected progress in the development of Tianmai Bio’s core product, oral insulin. Tianmai Bio’s oral insulin product faced setbacks due to its failure to pass registration approval from the China Food and Drug Administration. Additionally, worldwide research and development of oral insulin has consistently faced technical bottlenecks, leading to an uncertain market outlook in this field. In the diabetes treatment sector, emerging GLP-1 drugs have become market hotspots, and China Resources Pharmaceutical has chosen to focus on this emerging area and optimize its asset portfolio. For Tianmai Bio, losing China Resources Pharmaceutical as a major shareholder means its future development faces uncertainty.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.